Misawa Toru, Sugiyama Tomoyo, Kanaji Yoshihisa, Hoshino Masahiro, Yamaguchi Masao, Hada Masahiro, Nagamine Tatsuhiro, Nogami Kai, Yasui Yumi, Usui Eisuke, Lee Tetsumin, Yonetsu Taishi, Sasano Tetsuo, Kakuta Tsunekazu
Department of Cardiovascular Medicine, Tsuchiura Kyodo General Hospital, Ibaraki 300-0028, Japan.
Department of Interventional Cardiology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
World J Nephrol. 2021 Mar 25;10(2):8-20. doi: 10.5527/wjn.v10.i2.8.
Low-molecular-weight dextran (LMWD) is considered a safe alternative to contrast media for blood displacement during optical coherence tomography (OCT) imaging.
To investigate whether the use of LMWD for OCT is protective against kidney injury in patients with advanced renal insufficiency.
In this retrospective cohort study, we identified 421 patients with advanced renal insufficiency (estimated glomerular filtration rate < 45 mL/min/1.73 m) who underwent coronary angiography or percutaneous coronary intervention; 79 patients who used additional LMWD for OCT imaging (LMWD group) and 342 patients who used contrast medium exclusively (control group). We evaluated the differences between these two groups and performed a propensity score-matched subgroup comparison.
The median total volume of contrast medium was 133.0 mL in the control group 140.0 mL in the LMWD group. Although baseline renal function was not statistically different between these two groups, the LMWD group demonstrated a strong trend toward the progression of renal insufficiency as indicated by the greater change in serum creatinine level during the 1-year follow-up compared with the control group. Patients in the LMWD group experienced worsening renal function more frequently than patients in the control group. Propensity score matching adjusted for total contrast media volume consistently indicated a trend toward worsening renal function in the LMWD group at the 1-year follow-up. Delta serum creatinine at 1-year follow-up was significantly greater in the LMWD group than that in the control group [0.06 (-0.06, 0.29) -0.04 (-0.23, 0.08) mg/dL, = 0.001], despite using similar contrast volume.
OCT using LMWD may not be protective against worsening renal function in patients with advanced renal insufficiency.
低分子量右旋糖酐(LMWD)被认为是光学相干断层扫描(OCT)成像期间用于血液置换的造影剂的安全替代品。
探讨在晚期肾功能不全患者中,OCT使用LMWD是否对肾损伤具有保护作用。
在这项回顾性队列研究中,我们纳入了421例晚期肾功能不全(估计肾小球滤过率<45 mL/min/1.73 m²)且接受冠状动脉造影或经皮冠状动脉介入治疗的患者;79例在OCT成像中额外使用LMWD的患者(LMWD组)和342例仅使用造影剂的患者(对照组)。我们评估了这两组之间的差异,并进行了倾向评分匹配的亚组比较。
对照组造影剂的中位总体积为133.0 mL,LMWD组为140.0 mL。尽管两组之间的基线肾功能无统计学差异,但与对照组相比,LMWD组在1年随访期间血清肌酐水平变化更大,显示出肾功能不全进展的强烈趋势。LMWD组患者肾功能恶化的频率高于对照组。倾向评分匹配调整造影剂总体积后,在1年随访时持续显示LMWD组肾功能有恶化趋势。尽管使用的造影剂体积相似,但LMWD组1年随访时血清肌酐的变化显著大于对照组[0.06(-0.06,0.29)对-0.04(-0.23,0.08)mg/dL,P = 0.001]。
在晚期肾功能不全患者中,使用LMWD的OCT可能无法预防肾功能恶化。